REPORTING OF SIDE EFFECTS: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.

NOVARTIS

IMPORTANT INFORMATION

ILARIS®
(canakinumab)
150 mg subcutaneous injection

For the treatment of Gouty Arthritis attacks

MHRA Approval: December 2017
JUN 2022 | MLRID 219310

NOVARTIS

Before starting canakinumab

- Infections: You should not be treated with canakinumab if you have an active infection.
- Vaccinations: Talk to your doctor about any vaccinations you may need before starting treatment with canakinumab.

During canakinumab treatment

- Risk of infections: Use of canakinumab is associated with an increased risk of infections, including serious infections.
- If you develop an infection, your canakinumab treatment might need to be interrupted. Tell your doctor immediately if you have a fever lasting longer than 3 days or other symptoms that might be due to an infection.
- Seek medical attention immediately if you develop symptoms such as:
  – prolonged fever, cough or headache, or
  – localised redness, warmth or swelling of your skin, or
  – persistent cough, weight loss and low-grade fever
- Pregnancy: If you received canakinumab while you were pregnant, it is important that you inform the baby's doctor or nurse before any vaccinations are given to your baby. Your baby should not receive live vaccines until at least 16 weeks after you received your last dose of canakinumab before giving birth.

Treatment Indication:

Please make sure to have a LIST OF ALL MEDICATIONS you are taking when visiting a healthcare professional.

Patient's name: _____

Date of first dose of canakinumab: _____

Canakinumab dose administered: _____

Doctor's name: _____ Doctor's phone: _____